Compounds > N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine
Page last updated: 2024-08-03 02:30:07

N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine

Description

N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID16045442
CHEMBL ID304929
SCHEMBL ID667895
CHEBI ID109555

Synonyms (13)

Synonym
BRD-K25280080-001-02-3
BIOMOLKI2_000083
BIOMOLKI_000079
NCGC00163394-01
CHEBI:109555
n-(3-ethynylphenyl)-6,7-dimethoxyquinazolin-4-amine
(6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine
bdbm50095259
CHEMBL304929 ,
CCG-100683
SCHEMBL667895
Q27188697
n-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine

Drug Classes (1)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency20.7328AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency26.2000AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.8107AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency37.6858AID504845
67.9K proteinVaccinia virusPotency19.7020AID720579; AID720580

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cyclin-G-associated kinaseHomo sapiens (human)IC500.0720AID1595621
Lysine-specific histone demethylase 1AHomo sapiens (human)IC5050.0000AID1773372
Epidermal growth factor receptorHomo sapiens (human)IC500.0380AID1595620; AID310063; AID473321; AID473322; AID473323
Fructose-1,6-bisphosphatase 1Sus scrofa (pig)IC501.6000AID160681
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC500.0705AID473322; AID473323
Fructose-1,6-bisphosphatase 1Homo sapiens (human)IC500.9000AID89523
Fructose-1,6-bisphosphatase 1 Rattus norvegicus (Norway rat)IC5010.0000AID195073
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)IC500.0705AID473322; AID473323
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)IC500.0705AID473322; AID473323
Histamine H3 receptorRattus norvegicus (Norway rat)IC500.9000AID89523

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cyclin-G-associated kinaseHomo sapiens (human)Kd0.0068AID1595619
Epidermal growth factor receptorHomo sapiens (human)Kd0.0006AID1595618

Bioassays (52)

Assay IDTitleYearJournalArticle
AID1595620Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473322Inhibition of EGFR Leu858Arg mutant by HTRF assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1595640Binding affinity to GAK in human SUM159 cell lysates by multiplexed inhibitor bead profiling-based LC-MS/MS analysis2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID89523Concentration required to inhibit the human liver recombinant fructose-1,6-bisphosphatase.2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
ISSN: 0960-894X		Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.
AID1595625Antiproliferative activity against human UMCHOR1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1589075Cytotoxicity in human WS1 cells assessed as reduction in cell viability incubated fro 48 hrs by alamar blue dye based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1815407Cytotoxicity against DENV infected human Huh-7 cells assessed as reduction in cell viability by alamar blue assay2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52ISSN: 1464-3405Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).
AID1589080Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 20 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1815409Cytotoxicity against Venezuelan equine encephalitis virus TC-83 strain infected human U-87 MG cells assessed as reduction in cell viability by alamar blue assay2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52ISSN: 1464-3405Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).
AID1595636Effect on total EGFR expression in human UCH2 cells at 1 to 10 uM measured after 4 hrs by Western blot analysis2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473329Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 and Thr790Met mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1595618Binding affinity to wild-type human partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system by Kinomescan method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473327Growth inhibition of mouse BA/F3 cells expressing EGFR L858R mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1815406Antiviral activity against DENV2 New Guinea C strain infected in human Huh7 cells assessed as reduction in viral infection measured after 48 hrs post infection by renilla luciferase assay relative to control2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52ISSN: 1464-3405Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).
AID1595624Antiproliferative activity against human UCH7 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595638Inhibition of EGFR in human UCH2 cells assessed as reduction in EGF-induced EGFR phosphorylation at Y1068 residue at 10 uM preincubated for 4 hrs followed by EGF--stimulation and measured after 15 mins by Western blot analysis relative to control2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595627Antiproliferative activity against human UCH12 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595635Effect on total EGFR expression in human UCH1 cells at 1 to 10 uM measured after 4 hrs by Western blot analysis2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595626Antiproliferative activity against human CH22 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473325Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1589079Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 10 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID160681Compound was evaluated for its concentration required to inhibit the porcine kidney F16BPase2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
ISSN: 0960-894X		Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.
AID195073Compound was evaluated for its concentration required to inhibit the rat liver F16BPase2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
ISSN: 0960-894X		Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.
AID1595619Binding affinity to wild-type human partial length GAK (G13 to Y338 residues) expressed in bacterial expression system by Kinomescan method2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473324Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1595617Antiproliferative activity against human UCH2 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID684832Inhibition of human recombinant FBPase using fructose-1,6-biphosphate as substrate incubated for 3 mins prior to substrate addition by spectrophotometric analysis2012European journal of medicinal chemistry, Oct, Volume: 56ISSN: 1768-3254Ligand-based designing, in silico screening, and biological evaluation of new potent fructose-1,6-bisphosphatase (FBPase) inhibitors.
AID1595621Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1589078Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as relative luminescence by measuring ratio of RLU (test compound)/RLU(no compound) at 5 uM by luminescence based assay2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1595644Binding affinity to EGFR in human SUM159 cell lysates by multiplexed inhibitor bead profiling-based LC-MS/MS analysis2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1815408Antiviral activity against Venezuelan equine encephalitis virus TC-83 strain infected in human U-87 MG cells assessed as reduction in viral infection measured after 18 hrs post infection by Nano luciferase assay relative to control2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52ISSN: 1464-3405Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).
AID165448Compound was evaluated for its concentration required to inhibit the rabbit liver F16BPase2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
ISSN: 0960-894X		Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.
AID1595623Cytotoxicity against human WS1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473523Growth inhibition of mouse BA/F3 cells expressing EGFR L858R and Thr790Met mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1595615Inhibition of EGFR in human UCH1 cells assessed as reduction in EGF-induced EGFR phosphorylation at Y1068 residue at 10 uM preincubated for 4 hrs followed by EGF--stimulation and measured after 15 mins by Western blot analysis relative to control2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473321Inhibition of wild type EGFR by HTRF assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID473328Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 and Thr790Met mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1773372Inhibition of recombinant full length LSD1 (unknown origin) transfected in Escherichia coli BL21 (DE) using H3K4me2 as substrate by flourescence based analysis2021European journal of medicinal chemistry, Dec-05, Volume: 225ISSN: 1768-3254
AID1589082Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as luminescence signal at 1.3 uM by luminescence based assay relative to untreated control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID473323Inhibition of EGFR Leu858Arg and Thr790Met mutant by HTRF assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID473330Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 and Thr790Met mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1595628Antiproliferative activity against human UCH14 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID310063Inhibition of EGFR2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
ISSN: 0960-894X		Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
AID1595639Inhibition of EGFR in human UCH2 cells assessed as reduction in EGF-induced EGFR phosphorylation at Y1068 residue at 1 uM preincubated for 4 hrs followed by EGF--stimulation and measured after 15 mins by Western blot analysis relative to control2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595616Antiproliferative activity against human UCH1 cells measured after 72 hrs by alamar blue assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID1595637Inhibition of EGFR in human UCH1 cells assessed as reduction in EGF-induced EGFR phosphorylation at Y1068 residue at 1 uM preincubated for 4 hrs followed by EGF--stimulation and measured after 15 mins by Western blot analysis relative to control2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804		Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
AID473326Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 mutant after 96 hrs by cell titer-glo assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
ISSN: 1520-4804		Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
AID1589083Anti-tubercular activity against Mycobacterium tuberculosis H37Rv expressing LuxABCDE assessed as luminescence signal at 2.5 uM by luminescence based assay relative to untreated control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
ISSN: 1464-3405		Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's5 (45.45)24.3611
2020's4 (36.36)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
rtki cpd
0
aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector		00low000000
alfuzosin
0
monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent		00low000000
bunazosin
0
quinazolines00low000000
cgs 15943
0
aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant		00low000000
cl 387785
0
bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist		00low000000
doxazosin
0
aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent		00low000000
whi p97
0
quinazolines00low000000
ketanserin
0
aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist		00low000000
metolazone
0
organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor		00low000000
pd 153035
0
aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist		00low000000
pd168393
0
acrylamides;
bromobenzenes;
quinazolines;
secondary carboxamide;
substituted aniline		epidermal growth factor receptor antagonist00low000000
prazosin
0
aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		00low000000
terazosin
0
furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent		00low000000
methaqualone
0
quinazolinesGABA agonist;
sedative		00low000000
quinethazone
0
quinazolinesantihypertensive agent;
diuretic		00low000000
quinazolines
0
azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines		00low000000
mecloqualone
0
quinazolines00low000000
quinelorane
0
quinazolines00low000000
halofuginone
0
quinazolines00low000000
glycosine
0
quinazolines00low000000
febrifugine
0
quinazolines00low000000
2,3-trimethylene-4-quinazolone
0
quinazolines00low000000
fenquizone
0
quinazolines00low000000
fenazaquin
0
quinazolinesacaricide;
mitochondrial NADH:ubiquinone reductase inhibitor		00low000000
fluquinconazole
0
conazole fungicide;
dichlorobenzene;
organofluorine compound;
quinazolines;
triazole fungicide;
triazoles		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor		00low000000
gefitinib
0
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		00low000000
cyclazosin
0
aromatic amide;
aromatic ether;
furans;
monocarboxylic acid amide;
quinazolines;
quinoxaline derivative		adenosine A2A receptor antagonist00low000000
glyantrypine
0
quinazolines00low000000
canertinib
0
monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		00low000000
erlotinib
0
aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor		00low000000
lapatinib
0
furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		00low000000
(5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone
0
quinazolines00low000000
mrs 1220
0
quinazolines00low000000
3-deoxyvasicine
0
quinazolines00low000000
N-benzylquinazolin-4-amine
0
benzenes;
quinazolines;
secondary amino compound		00low000000
2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
N-(cyclohexylmethyl)-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazolin-9-amine
0
quinazolines00low000000
N-(2-pyridinylmethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine
0
quinazolines00low000000
N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide
0
quinazolines00low000000
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[3-(2-furanylmethyl)-4-oxo-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
2-pyridin-4-yl-2,3-dihydro-1H-quinazolin-4-one
0
quinazolines00low000000
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine
0
quinazolines00low000000
2-[(2-cyclohexyl-4-quinazolinyl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide
0
quinazolines00low000000
3-[[[[3-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-6-quinazolinyl]amino]-oxomethyl]amino]propanoic acid ethyl ester
0
quinazolines00low000000
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone
0
quinazolines00low000000
2-[(3-ethyl-4-oxo-2-quinazolinyl)thio]acetic acid cyclohexyl ester
0
quinazolines00low000000
2-thiophen-2-yl-2,3-dihydro-1H-quinazolin-4-one
0
quinazolines00low000000
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline
0
pyridines;
pyrrolidines;
quinazolines		00low000000
5-methyl-6-pyridin-4-yl-6H-benzimidazolo[1,2-c]quinazoline
0
quinazolines00low000000
2-[[2-[(2-methoxy-2-oxoethyl)thio]-4-oxo-3-quinazolinyl]oxy]acetic acid methyl ester
0
quinazolines00low000000
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
0
quinazolines00low000000
3-methoxy-2-(3-pyridinylmethylthio)-4-quinazolinone
0
quinazolines00low000000
3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one
0
quinazolines00low000000
N1-(6-bromo-4-quinazolinyl)-N4,N4-dimethylbenzene-1,4-diamine
0
quinazolines00low000000
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine
0
aromatic amine;
monofluorobenzenes;
pyridines;
quinazolines;
secondary amino compound;
substituted aniline		00low000000
3-methyl-2-[2-(4-methyl-5-thiazolyl)ethylthio]-4-quinazolinone
0
quinazolines00low000000
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide
0
quinazolines00low000000
6-bromo-3-phenyl-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine
0
piperidines;
quinazolines;
tertiary amino compound;
toluenes		00low000000
2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone
0
quinazolines00low000000
2-(4-methoxyphenyl)-3-(3-pyridinyl)-4-quinazolinone
0
quinazolines00low000000
2-phenyl-1H-quinazoline-4-thione
0
quinazolines00low000000
2-(ethylthio)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one
0
quinazolines00low000000
2-[(3-methyl-4-oxo-2-quinazolinyl)thio]-N-phenylacetamide
0
quinazolines00low000000
1,3-dimethyl-6-(4-morpholinylsulfonyl)quinazoline-2,4-dione
0
quinazolines00low000000
6,7-dimethoxy-3-phenyl-1H-quinazoline-2,4-dione
0
quinazolines00low000000
6-methoxy-4-methyl-2-[(2-methylphenyl)methylthio]quinazoline
0
quinazolines00low000000
2-(4-chlorophenyl)-4-propan-2-yloxyquinazoline
0
quinazolines00low000000
7-bromo-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline
0
quinazolines00low000000
2-(3-methoxyphenyl)-4-propan-2-yloxyquinazoline
0
quinazolines00low000000
2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone
0
quinazolines00low000000
N-(phenylmethyl)-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide
0
quinazolines00low000000
2-(6-amino-2-methyl-4-oxo-3-quinazolinyl)-N-(2-methylphenyl)acetamide
0
quinazolines00low000000
6-amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone
0
quinazolines00low000000
2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine
0
quinazolines00low000000
4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester
0
quinazolines00low000000
4-(4-anilinoanilino)-2-quinazolinecarboxylic acid ethyl ester
0
quinazolines00low000000
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone
0
quinazolines00low000000
N-(2,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-quinazolinamine
0
quinazolines00low000000
3-(4-oxo-3-quinazolinyl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide
0
quinazolines00low000000
4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide
0
quinazolines00low000000
N-(4-methoxyphenyl)-2-(3-nitrophenyl)-4-quinazolinamine
0
quinazolines00low000000
2-[(2-tert-butyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
0
quinazolines00low000000
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[2-(phenylmethyl)-4-quinazolinyl]thio]ethanone
0
quinazolines00low000000
2-[(2-propyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide
0
quinazolines00low000000
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[(2-propyl-4-quinazolinyl)thio]ethanone
0
quinazolines00low000000
N-(5-methyl-3-isoxazolyl)-2-[(2-propan-2-yl-4-quinazolinyl)thio]acetamide
0
quinazolines00low000000
Src Inhibitor-1
0
aromatic ether;
polyether;
quinazolines;
secondary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor00low000000
6,7-dimethoxy-N-[(4-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
9-methyl-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazoline
0
quinazolines00low000000
2-[(2,4-dichlorophenyl)methylthio]-6,7-dimethoxy-3-(thiophen-2-ylmethyl)-4-quinazolinimine
0
quinazolines00low000000
7-chloro-N-(2-furanylmethyl)-4-quinazolinamine
0
quinazolines00low000000
4-methoxy-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide
0
quinazolines00low000000
SMER 28
0
organobromine compound;
quinazolines;
secondary amino compound		autophagy inducer00low000000
4-methoxy-2-(4-propoxyphenyl)quinazoline
0
quinazolines00low000000
2-butoxy-3-phenyl-4-quinazolinone
0
quinazolines00low000000
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine
0
pyridines;
quinazolines;
tertiary amino compound		00low000000
4-chloro-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide
0
quinazolines00low000000
2-(2-bromophenyl)-5-[(7-nitro-4-quinazolinyl)oxymethyl]-1,3,4-oxadiazole
0
quinazolines00low000000
3-[[4-(2-benzofuranyl)-2-thiazolyl]methyl]-2-[(dimethylamino)methyl]-4-quinazolinone
0
quinazolines00low000000
3-(benzenesulfonyl)-N-(3-methylphenyl)-5-triazolo[1,5-a]quinazolinamine
0
quinazolines00low000000
4-[2-[[3-(4-methylphenyl)-5-triazolo[1,5-a]quinazolinyl]amino]ethyl]benzenesulfonamide
0
quinazolines00low000000
6-bromo-3-[4-nitro-3-(trifluoromethyl)phenyl]-2-propyl-4-quinazolinone
0
quinazolines00low000000
12-oxo-N-(4-phenyl-2-thiazolyl)-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazoline-3-carboxamide
0
quinazolines00low000000
4,5-dimethyl-2-[[1-oxo-2-(4-quinazolinyloxy)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester
0
quinazolines00low000000
7-[(6,8-dichloro-4-quinazolinyl)oxymethyl]-5-thiazolo[3,2-a]pyrimidinone
0
quinazolines00low000000
N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-(2-fluorophenyl)-4-oxo-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
2-[[3-(2,4-difluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide
0
quinazolines00low000000
2-[[3-[(4-fluorophenyl)methyl]-4-oxo-2-quinazolinyl]thio]-N-(thiophen-2-ylmethyl)acetamide
0
quinazolines00low000000
3-(2-furanylmethyl)-4-oxo-N,N-dipropyl-2-sulfanylidene-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
7-(4-quinazolinyloxymethyl)-5-thiazolo[3,2-a]pyrimidinone
0
quinazolines00low000000
N'-(4-quinazolinyl)acetohydrazide
0
quinazolines00low000000
4-methyl-N'-(4-quinazolinyl)benzohydrazide
0
quinazolines00low000000
N-{3-[(2-phenylquinazolin-4-yl)amino]phenyl}acetamide
0
acetamide;
aromatic amine;
quinazolines;
secondary amino compound;
substituted aniline		00low000000
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide
0
quinazolines00low000000
2-[(3-butyl-4-oxo-2-quinazolinyl)thio]-N-cyclopropylacetamide
0
quinazolines00low000000
N4-(5-Fluoro-4-imino-3,4-dihydroquinazolin-3-yl)isonicotinamide
0
quinazolines00low000000
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(4-chlorophenyl)methyl]-4-(prop-2-enylthio)quinazoline
0
quinazolines00low000000
2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine
0
quinazolines00low000000
7-chloro-2-methyl-3-(4-pyridylmethyl)-3,4-dihydroquinazolin-4-one
0
quinazolines00low000000
2-[(7-chloro-4-quinazolinyl)oxy]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone
0
quinazolines00low000000
3,3-dimethyl-1-[[9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl]thio]-2-butanone
0
quinazolines00low000000
2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine
0
quinazolines00low000000
LSM-19241
0
quinazolines00low000000
LSM-19663
0
quinazolines00low000000
N-[7-(2-furanyl)-5-oxo-7,8-dihydro-6H-quinazolin-2-yl]acetamide
0
quinazolines00low000000
2-(2,4-dichlorophenyl)-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
4-(3-methoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione
0
quinazolines00low000000
4-[[3-[2-(1-cyclohexenyl)ethyl]-4-oxo-2-sulfanylidene-1H-quinazolin-7-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester
0
quinazolines00low000000
2-(3-nitrophenyl)-N-(phenylmethyl)-4-quinazolinamine
0
quinazolines00low000000
3-(2-furanylmethyl)-2-phenyl-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
LSM-19894
0
quinazolines00low000000
importazole
0
quinazolines00low000000
2-(1,3-benzothiazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one
0
quinazolines00low000000
6,7-dimethoxy-3-(2-oxolanylmethyl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
4-(6-quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione
0
quinazolines00low000000
9-phenyl-1,5,6,7,8,9-hexahydro-[1,2,4]triazolo[5,1-b]quinazoline
0
quinazolines00low000000
2-[(3-butan-2-yl-4-oxo-2-quinazolinyl)thio]propanenitrile
0
quinazolines00low000000
altanserin
0
quinazolines00low000000
tandutinib
0
aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		00low000000
zd 6474
0
aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor		00low000000
N-[3,5-dimethyl-1-[(4-methylphenyl)methyl]-4-pyrazolyl]-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide
0
quinazolines00low000000
2-(methylthio)-6-phenyl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one
0
quinazolines00low000000
N'-[2-[(2-cyclohexyl-4-quinazolinyl)thio]-1-oxoethyl]-2-methylpropanehydrazide
0
quinazolines00low000000
1-(3,5-dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone
0
quinazolines00low000000
ml106
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine
0
quinazolines00low000000
N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine
0
quinazolines00low000000
6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine
0
quinazolines00low000000
2-[5-[[2-(3-methoxypropylamino)-2-oxoethyl]thio]-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]-N-(phenylmethyl)acetamide
0
quinazolines00low000000
3-[6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-oxohexyl]-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
3-[2-[butyl(methyl)amino]ethyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide
0
quinazolines00low000000
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
2-[(3-oxo-2-propan-2-yl-2H-imidazo[1,2-c]quinazolin-5-yl)thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide
0
quinazolines00low000000
2-(6-benzimidazolo[1,2-c]quinazolinylthio)-N-(2-furanylmethyl)acetamide
0
quinazolines00low000000
2-(3-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one
0
quinazolines00low000000
3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
5a,6,7,8,9,10-hexahydro-5H-azepino[2,1-b]quinazolin-12-one
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
6,7-diethoxy-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
5-(6,7-diethoxy-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-(2-furanylmethyl)pentanamide
0
quinazolines00low000000
6-chloro-3-[2-(diethylamino)ethyl]-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
4-[1,3-dioxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propyl]-1-piperazinecarboxylic acid ethyl ester
0
quinazolines00low000000
N-butyl-2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
6,7-diethoxy-3-(3-methoxypropyl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
savirin
0
quinazolines00low000000
4-[(6,7-diethoxy-2,4-dioxo-1H-quinazolin-3-yl)methyl]-N-(3-methoxypropyl)-1-cyclohexanecarboxamide
0
quinazolines00low000000
6,7-dimethoxy-4-(2-oxolanylmethylamino)-1H-quinazoline-2-thione
0
quinazolines00low000000
N-(5-methyl-1H-pyrazol-3-yl)-2-[[3-oxo-2-(phenylmethyl)-2H-imidazo[1,2-c]quinazolin-5-yl]thio]acetamide
0
quinazolines00low000000
3-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-quinazolinone
0
quinazolines00low000000
2-[2,4-dioxo-3-(phenylmethyl)-1-quinazolinyl]-N-(5-methyl-3-isoxazolyl)acetamide
0
quinazolines00low000000
2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one
0
quinazolines00low000000
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester
0
quinazolines00low000000
3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea
0
quinazolines00low000000
3-[3-(N-ethylanilino)propyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
8-methylene-7-(phenylmethyl)-5H-[1,3]dioxolo[4,5-g]quinazoline-6-thione
0
quinazolines00low000000
2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide
0
quinazolines00low000000
N-[2-[(3-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide
0
quinazolines00low000000
7-chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone
0
quinazolines00low000000
3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one
0
quinazolines00low000000
3-(2-methoxyphenyl)-2-methyl-4-oxo-1H-quinazoline-2-carboxylic acid methyl ester
0
quinazolines00low000000
1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea
0
quinazolines00low000000
N,N-diethyl-2-[[7-[(4-methoxyphenyl)methyl]-8-oxo-[1,3]dioxolo[4,5-g]quinazolin-6-yl]thio]acetamide
0
quinazolines00low000000
6-(4-morpholinyl)-3-(2-phenylethyl)-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-[6-(4-morpholinyl)-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl]hexanamide
0
quinazolines00low000000
N-[4-oxo-2-(2-pyridinyl)-1,2-dihydroquinazolin-3-yl]acetamide
0
quinazolines00low000000
N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide
0
quinazolines00low000000
3-(2-fluorophenyl)-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester
0
quinazolines00low000000
2-(2-bromophenyl)-3-[3-(4-morpholinyl)propyl]-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
sch 79797
0
quinazolines00low000000
3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one
0
quinazolines00low000000
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone
0
quinazolines00low000000
N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester
0
quinazolines00low000000
2-(4-morpholinyl)-10-pyridazino[6,1-b]quinazolinone
0
quinazolines00low000000
N-(4-ethylphenyl)-2-[[3-[3-(4-methyl-1-piperidinyl)propyl]-4-oxo-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
N-(3-{[2-(2-fluorophenyl)quinazolin-4-yl]amino}phenyl)acetamide
0
acetamide;
aromatic amine;
monofluorobenzenes;
quinazolines;
secondary amino compound;
substituted aniline		00low000000
1-cyclohexyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea
0
quinazolines00low000000
N-(2-methoxyethyl)-4-oxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one
0
quinazolines00low000000
6-(6-bromo-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-[2-(4-sulfamoylphenyl)ethyl]hexanamide
0
quinazolines00low000000
N-(3-methoxyphenyl)-2-[(4-oxo-3-propyl-2-quinazolinyl)thio]-2-phenylacetamide
0
quinazolines00low000000
2-thiophen-2-yl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine
0
aromatic amine;
piperidines;
pyridines;
quinazolines;
secondary amino compound;
tertiary amino compound		00low000000
2-(4-oxo-3-quinazolinyl)-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide
0
quinazolines00low000000
N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester
0
quinazolines00low000000
7-chloro-3-[2-(1-cyclohexenyl)ethyl]-2-sulfanylidene-1H-quinazolin-4-one
0
quinazolines00low000000
4-[2-[[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]thio]-4-oxo-3-quinazolinyl]-N-(phenylmethyl)butanamide
0
quinazolines00low000000
2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
4-(3,4-dimethoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione
0
quinazolines00low000000
2-[3-(1-benzotriazolylmethyl)-4-methoxyphenyl]-3-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
cb676475
0
quinazolines00low000000
1,5-dioxo-2,4-dihydropyrrolo[1,2-a]quinazoline-3-carboxylic acid ethyl ester
0
quinazolines00low000000
GSK3-XIII
0
aromatic amine;
pyrazoles;
quinazolines;
secondary amino compound		EC 2.7.11.26 (tau-protein kinase) inhibitor00low000000
2-(1,3-benzoxazol-2-ylamino)-7,7-dimethyl-4-(2-pyridinyl)-1,4,6,8-tetrahydroquinazolin-5-one
0
quinazolines00low000000
N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine
0
quinazolines00low000000
N-[3-(4-morpholinyl)propyl]-2,4-dioxo-3-(2-phenylethyl)-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
3-(2-methoxyethyl)-2,4-dioxo-N-pentyl-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
2-[(1-amino-1-oxopropan-2-yl)thio]-3-butyl-4-oxo-7-quinazolinecarboxylic acid methyl ester
0
quinazolines00low000000
ic 87114
0
6-aminopurines;
biaryl;
quinazolines		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor00low000000
zm 447439
0
aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor		00low000000
linagliptin
0
aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		00low000000
bibw 2992
0
aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor		00low000000
sotrastaurin
0
indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines		anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent		00low000000
saracatinib
0
aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent		00low000000
luotonin a
0
quinazolines00low000000
PDGF receptor tyrosine kinase inhibitor III
0
aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
quinazolines;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor00low000000
erastin
0
aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide		antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor		00low000000
azd 8931
0
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist		00low000000
azd 1152
0
anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor;
prodrug		00low000000
pf 00299804
0
enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		00low000000
lapatinib ditosylate
0
quinazolines00low000000
idelalisib
0
aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor		00low000000
N-(2-methoxyethyl)-2-[[3-[(4-methoxyphenyl)methyl]-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide
0
quinazolines00low000000
4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxo-N-propan-2-ylbutanamide
0
quinazolines00low000000
N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide
0
quinazolines00low000000
2-[4-[1-[(2-fluorophenyl)methyl]-2,4-dioxo-3-quinazolinyl]phenyl]-N-(2-oxolanylmethyl)acetamide
0
quinazolines00low000000
2-[6,7-dimethoxy-3-(3-methoxyphenyl)-2,4-dioxo-1-quinazolinyl]-N-(5-methyl-1H-pyrazol-3-yl)acetamide
0
quinazolines00low000000
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide
0
quinazolines00low000000
1-[(4-methylphenyl)methyl]-2,4-dioxo-N-(phenylmethyl)-3-prop-2-enyl-7-quinazolinecarboxamide
0
quinazolines00low000000
3-[(4-methoxyphenyl)methyl]-N-(3-methoxypropyl)-2,4-dioxo-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
2-[1-(4-bromophenoxy)butyl]-8,9-dimethoxy-3H-[1,2,4]triazolo[1,5-c]quinazoline-5-thione
0
quinazolines00low000000
azd 1152-hqpa
0
anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
Aurora kinase inhibitor		00low000000
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide
0
quinazolines00low000000
chaetominine
0
indole alkaloid;
lactam;
organic heterotetracyclic compound;
quinazolines		metabolite00low000000
N-[3-(1-azepanyl)propyl]-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
0
quinazolines00low000000
2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide
0
quinazolines00low000000
2-[[2-[2-(1-piperidinyl)ethyl]-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide
0
quinazolines00low000000
3-(4-methylphenyl)-5-oxo-N-propyl-8-thiazolo[2,3-b]quinazolinecarboxamide
0
quinazolines00low000000
3-(4-methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide
0
quinazolines00low000000
zm323881
0
aromatic ether;
benzyl ether;
fluorophenol;
halophenol;
monofluorobenzenes;
organic cation;
quinazolines;
secondary amino compound;
substituted aniline		vascular endothelial growth factor receptor antagonist00low000000
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methoxyphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3,5-dimethyl-4-isoxazolyl)-N-[(2-ethoxyphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
N-[4-[[[6-(3,5-dimethyl-4-isoxazolyl)-4-quinazolinyl]amino]methyl]phenyl]acetamide
0
quinazolines00low000000
6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3,5-dimethyl-4-isoxazolyl)-N-[1-(2-furanyl)ethyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol
0
quinazolines00low000000
ast 1306
0
quinazolines00low000000
2-[[2-(phenoxymethyl)-4-quinazolinyl]thio]acetic acid methyl ester
0
quinazolines00low000000
poziotinib
0
acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline		antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist		00low000000
N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide
0
quinazolines00low000000
N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine
0
quinazolines00low000000
6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine
0
quinazolines00low000000
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine
0
quinazolines00low000000
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
0
quinazolines00low000000
4-[5-(3-hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile
0
quinazolines00low000000
2-[5-(2-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
3-hydroxy-2-(5-thiophen-2-yl-2-furanyl)-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
2-[5-(3-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
3-hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one
0
quinazolines00low000000
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine
0
quinazolines00low000000
cp 466722
0
quinazolines00low000000
[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol
0
quinazolines00low000000
unc 0638
0
quinazolines00low000000
unc 0321
0
quinazolines00low000000
ML240
0
aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent00low000000
ncgc00242364
0
quinazolines00low000000
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide
0
aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes		00low000000
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
0
quinazolines00low000000
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
0
quinazolines00low000000
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide
0
quinazolines00low000000
nu 1025
0
phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor00low000000
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea
0
quinazolines00low000000
4-oxo-2-(trifluoromethyl)-1H-quinazoline-6-carboxylic acid ethyl ester
0
quinazolines00low000000
4-hydroxyquinazoline
0
quinazolines00low000000
2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(2-methyl-2,3-dihydroindol-1-yl)methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester
0
quinazolines00low000000
2-[[[5,7-bis(ethylamino)-[1,2,4]triazolo[4,3-a][1,3,5]triazin-3-yl]thio]methyl]-1H-quinazolin-4-one
0
quinazolines00low000000
3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester
0
quinazolines00low000000
N-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide
0
quinazolines00low000000
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea
0
quinazolines00low000000
6,8-dibromo-2-[[[4-(difluoromethoxy)phenyl]methyl-methylamino]methyl]-1H-quinazolin-4-one
0
quinazolines00low000000
2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3h)-quinazolinone
0
aryl phosphate;
monochlorobenzenes;
quinazolines		fluorochrome00low000000
glycosminine
0
quinazolines00low000000
N-[(4-oxo-1H-quinazolin-2-yl)methyl]-N-(2-phenylethyl)butanamide
0
quinazolines00low000000
2-(4-methoxyphenyl)-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1H-pyrimidin-4-one
0
quinazolines00low000000
6,7-dimethoxy-2-[(1H-1,2,4-triazol-5-ylthio)methyl]-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one
0
quinazolines00low000000
2-(diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one
0
quinazolines00low000000
2-[5-(3-chlorophenyl)-2-furanyl]-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(2-pyridinylthio)methyl]-1H-quinazolin-4-one
0
quinazolines00low000000
5,5-diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one
0
quinazolines00low000000
1-[(7-chloro-4-oxo-1H-quinazolin-2-yl)methyl]-4-piperidinecarboxamide
0
quinazolines00low000000
3-ethyl-2-[(4-oxo-1H-quinazolin-2-yl)methylthio]-4-quinazolinone
0
quinazolines00low000000
6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one
0
quinazolines00low000000
2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one
0
quinazolines00low000000
5,5-diethyl-2-hydrazinyl-1,6-dihydrobenzo[h]quinazolin-4-one
0
quinazolines00low000000
3-(3-ethoxypropyl)-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-1-(phenylmethyl)thiourea
0
quinazolines00low000000
chrysogine
0
cyclic amide;
quinazoline alkaloid;
quinazolines;
secondary alcohol;
secondary amide		Aspergillus metabolite;
biological pigment;
marine metabolite		00low000000
N-[(cyclohexylamino)-oxomethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide
0
quinazolines00low000000
7-[[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-5-thiazolo[3,2-a]pyrimidinone
0
quinazolines00low000000
2-[[(6-ethyl-4-oxo-3-prop-2-enyl-2-thieno[2,3-d]pyrimidinyl)thio]methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester
0
quinazolines00low000000
ARS-1620
0
quinazolinesantineoplastic agent;
antiviral agent;
inhibitor		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
rtki cpd
2
aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector		2001201217.5medium000110
pd 153035
4
aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist		2001201911.2medium000130
pd168393
1
acrylamides;
bromobenzenes;
quinazolines;
secondary carboxamide;
substituted aniline		epidermal growth factor receptor antagonist2010201014.0low000100
adenosine monophosphate
2
adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		2001201217.5low000110
gefitinib
3
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		200720199.0low000120
canertinib
1
monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
erlotinib
5
aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor		200720218.8medium000221
lapatinib
2
furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000020
mdl29,951
1
2012201212.0low000010
zd 6474
1
aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
bosutinib
1
aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
ekb 569
1
aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor201920195.0low000010
hki 272
1
nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
bibw 2992
1
aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
saracatinib
1
aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent		201920195.0low000010
exel-7647
1
201920195.0medium000010
bms-690514
1
201920195.0low000010
azd 8931
1
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist		201920195.0medium000010
pf 00299804
1
enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		201920195.0low000010
poziotinib
1
acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline		antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist		201920195.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Chordoma0
1
201920195.0high000010
Congenital Zika Syndrome0
1
202020204.0high000010
Disease Models, Animal0
1
202020204.0high000010
Zika Virus Infection0
1
202020204.0high000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019